Vitalhub (TSE:VHI) Upgraded to “Moderate Buy” at Raymond James

Raymond James upgraded shares of Vitalhub (TSE:VHI) to a moderate buy rating in a research report report published on Wednesday,Zacks.com reports.

A number of other research analysts have also commented on the stock. Scotiabank set a C$14.00 price target on shares of Vitalhub and gave the company an “outperform” rating in a research note on Thursday, January 30th. Canaccord Genuity Group increased their target price on Vitalhub from C$12.00 to C$12.50 and gave the stock a “buy” rating in a research note on Thursday, January 16th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Vitalhub currently has a consensus rating of “Buy” and an average target price of C$11.92.

Vitalhub Price Performance

VHI stock opened at C$9.66 on Wednesday. Vitalhub has a one year low of C$5.80 and a one year high of C$12.09. The stock has a market cap of C$522.53 million, a price-to-earnings ratio of 157.12, a price-to-earnings-growth ratio of 1.18 and a beta of 1.26. The company has a fifty day moving average price of C$10.49 and a two-hundred day moving average price of C$10.31.

About Vitalhub

Vitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination and optimization, and patient flow, engagement, and operational visibility solutions.